Regulation and funciton of Glucagon-Like Peptide 1 and 2 under inflammatory conditions
Year: 2019
Type: dissertation
Abstract: Glucagon-like Peptide 1 is a key component of food dependent insulin secretion. The co-secreted, intestinotrope GLP-2 increases intestinal cell proliferation as well as nutrient absorption in the intestine. Further GLP-1 has cardioprotective properties leading to improvement of cardiac contractility and myocardial function. The mechanisms of cardioprotection are not understood. A direct mechanism seems unlikely as GLP-1 receptors are not expressed on ventricular cardiomyocytes and GLP-1R agonists stay effective in GLP-1R-Knockout mice. GLP-1 is metabolized in a dipeptidedylpeptidase 4 dependent manner, thus DPP-4 Inhibitors (i.e. Linagliptin) can increase GLP-1 levels. DPP-4 inhibitors and GLP-1 agonists are used for the therapy of diabetes mellitus. In cardiovascular diseases such as acute myocardial infarction, pro-inflammatory cytokines are secreted, which have been identified as a stimulus of GLP-1 secretion. This study investigates the cardioprotective relevance of GLP-1 during acute myocardial infarction (MI) in a mouse model (LAD-Ligation) and in patient samples. Patient samples as well as the mouse model showed a transient increase of GLP-1 serum levels after MI. Treatment of mice with the DPP-4 inhibitor Linagliptin increased GLP-1 levels and cardiac contractility. An inverse agonist of the GLP-1R (Exendin-9) and usage of GLP-1R-KO mice prevented this effect, indicating involvement of the GLP-1R. Linagliptin and exogenous GLP-1 increased the respiratory capacity in isolated mitochondria from non-infarcted murine heart tissue, which could explain the improvement of cardiac contractility. On a protein level, the expression of p-AMPK correlated with the effects of GLP-1. In addition, Linagliptin-dependent increase of cardiac contractility was abrogated by AMPK inhibition. These experiments demonstrate that MI is a sufficient stimulus to increase GLP-1 levels, which have cardio protective efficacy. Although these experiments give some molecular insight, the mechanisms of GLP-1R dependent cardio protection remain incompletely understood and will require additional studies. The second part of this study investigates the relevance of GLP-2 for inflammatory bowel diseases (IBD) using patient samples and IBD mouse models (dextran sodium sulfate (DSS), clostridium difficile infection (CDI)). Despite the established use of GLP-2 for the treatment of short bowel syndrome (SBS), its mechanism of action is incompletely understood. Patient samples with Crohn’s disease and ulcerative colitis, lipopolysaccharide (LPS) treated mice as well as mouse colitis models were found to have increased GLP-2 levels in comparison to the controls. Lipopolysaccharide treatment led to a dosage dependent increase of circulating GLP-2 levels in mice. The inflammatory GLP-2 secretion was attributed to pancreatic α-cells. In colitis models DPP-4 inhibition (by Linagliptin) lead to increased GLP-2 levels, reduced serum concentration of the pro inflammatory cytokine Interleukin-6 and improved disease severity. In addition, histological and functional analysis revealed reduced intestinal inflammation and improved gut barrier. In addition to DPP-4 inhibitors, GLP-2 agonists reduced intestinal inflammation (CDI-colitis model). This effect was abrogated by antagonization of the GLP-2R.The presented data demonstrates that inflammatory diseases processes (MI, IBD) increase serum levels of GLP-1/2, while both proteins help to control disease severity. We were able to demonstrate some molecular mechanisms relevant for protective effects. However, additional pre-clinical studies are required to further elucidate the underlying mechanisms.
Source: RWTH Publications (RWTH Aachen)
Author: Diebold, Sebastian
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: glucagon-like peptide-1, glucagon-like peptide-2, acute myocardial infarction, cardioprotection, cardiac contractility, DPP-4 inhibitors, linagliptin, GLP-1 receptor, AMPK signaling, mitochondrial respiration, inflammatory bowel disease, DSS-induced colitis, Clostridium difficile infection
Open Access status: green
OpenAlex ID: W6925324466
